Camoquin Hydrochloride

(Amodiaquine)

ApprovedSmall molecule

Camoquin Hydrochloride is one of 40 small molecule programs targeting Plasmodium falciparum malaria. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Plasmodium Falciparum MalariaApproved

MalariaUnknown status

Plasmodium Falciparum MalariaApproved

Approved

MalariaApproved

Unknown status

Competition

Competitive Landscape

94 competitors in Malaria

#DrugCompanyPhaseTrials

Dihydroartemisinin-Piperaquine

GSK

Phase 3

51 2

Camoquin Hydrochloride

PParkedale

Approved

10 3

Rabies Vaccine

Novartis

Phase 3

9 4

YF-Vax

Sanofi

Phase 3

1 5

Krintafel

GGlaxo Dba Glaxosmithkline

Phase 3

4 6

Artemether-Lumefantrine (AL)

Novartis

Phase 3

11 7

Artesunate-Amodiaquine

Sanofi

Phase 3

19 8

Pfspz Challenge

Merck & Co.

Phase 2

11 9

R21/matrix-M

UUniversity of Oxford

Phase 3

4 10

Pyramax

SShin Poong Pharmaceutical Co. Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malaria10 trials

Chloroquine and Amodiaquine for Treatment of Malaria in Children

Completed·BBandim Health Project·Phase 4·NCT00137514·720 enrolled

Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso

Completed·HHeidelberg University·Phase 2·NCT00261222·120 enrolled

Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01955382·70 enrolled

Show 7 more trials

Effectiveness, Feasibility and Acceptability of Seasonal Malaria Chemoprevention in Aweil South County in South Sudan

Unknown status·MMalaria Consortium·Phase 3·NCT05471544·3,575 enrolled

A Trial of Four Drug Regimens for the Prevention of Malaria in Senegalese Children

Completed·LLondon School of Hygiene and Tropical Medicine·Phase 3·NCT00132548·2,200 enrolled

A Comparative Safety and Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate in African Adult Patients With Uncomplicated Malaria

Completed· Sanofi logo

Sanofi·Phase 1/2·NCT00563914·72 enrolled

Safety and Efficacy of Methylene Blue Combined With Artesunate or Amodiaquine for Malaria Treatment in Children of Burkina Faso: a Pilot Study

Completed·HHeidelberg University·Phase 2·NCT00354380

Relationship Between HIV and Malaria in Ugandan Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT00356824·300 enrolled

Antimalarial Drug Resistance in Mali

Completed·CCenters for Disease Control and Prevention·N/A·NCT00127998·1,011 enrolled

Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children

Unknown status·LLondon School of Hygiene and Tropical Medicine·N/A·NCT05354258·600 enrolled

ART2 trials

Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects

Terminated·UUniversity of Oxford·Phase 1·NCT04080895·8 enrolled

Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects

Terminated·UUniversity of Oxford·Phase 1/2·NCT02696954·17 enrolled

Efficacy2 trials

Phase 2 Efficacy Study of Primaquine and Methylene Blue

Completed·UUniversity of California, San Francisco·Phase 2·NCT02831023·80 enrolled

Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali

Completed·LLondon School of Hygiene and Tropical Medicine·Phase 2·NCT05550909·100 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women

Completed·LLondon School of Hygiene and Tropical Medicine·Phase 3·NCT00131703·900 enrolled

Tolerance1 trial

Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance

Completed· Sanofi logo

Sanofi·Phase 4·NCT00445796·300 enrolled

3 more indications

MPA1 trial

A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00894660·38 enrolled

Long-term Follow-up1 trial

Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine

Completed· GSK logo

GSK·Phase 2·NCT00323622·1,737 enrolled

Prevention1 trial

Chemoprevention Efficacy Study in Burkina Faso

Unknown status·MMalaria Consortium·Phase 4·NCT05478954·800 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

CAMOQUIN HYDROCHLORIDE

NDA NDA006441

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Amodiaquine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amodiaquine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amodiaquine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA006441). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Parkedale company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PParkedale

Camoquin Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malaria10 trials

ART2 trials

Efficacy2 trials

Efficacy and Safety1 trial

Tolerance1 trial

MPA1 trial

Long-term Follow-up1 trial

Prevention1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News